{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:17:17Z","timestamp":1778008637950,"version":"3.51.4"},"reference-count":163,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T00:00:00Z","timestamp":1433376000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Developments increasing our understanding of chronic urticaria have resulted in the simplification and improvement of available treatments. Currently, many treatments target mast cell mediators, but we can now disrupt mast cell activation with the anti\u2010IgE antibody omalizumab, which has markedly advanced the treatment landscape for patients with difficult\u2010to\u2010treat urticaria. Current guidelines provide a framework for the management and treatment of patients with <jats:styled-content style=\"fixed-case\">CU<\/jats:styled-content> but, as each patient is different, knowledge and experience of specialist dermatologists and allergists are key to effective pharmacotherapy. This article reviews the different therapeutic options for patients with chronic spontaneous urticaria (also called chronic idiopathic urticaria) or chronic inducible urticaria and discusses management of special populations or special circumstances related to <jats:styled-content style=\"fixed-case\">CU<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/jdv.13198","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T17:40:26Z","timestamp":1433439626000},"page":"16-32","source":"Crossref","is-referenced-by-count":66,"title":["Management and treatment of chronic urticaria (<scp>CU<\/scp>)"],"prefix":"10.1111","volume":"29","author":[{"given":"M.","family":"Maurer","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy Allergie\u2010Centrum\u2010Charit\u00e9 Charit\u00e9 \u2012 Universitatsmedizin Berlin Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.K.","family":"Church","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Allergie\u2010Centrum\u2010Charit\u00e9 Charit\u00e9 \u2012 Universitatsmedizin Berlin Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gon\u00e7alo","sequence":"additional","affiliation":[{"name":"Clinic of Dermatology University Hospital and Faculty of Medicine University of Coimbra Coimbra Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Sussman","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology St. Michael's Hospital and University of Toronto Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"S\u00e1nchez\u2010Borges","sequence":"additional","affiliation":[{"name":"Allergy and Clinical Immunology Department Centro M\u00e9dico\u2010Docente La Trinidad Caracas Venezuela"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03256.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12313"},{"key":"e_1_2_9_4_1","first-page":"90","article-title":"Chronic urticaria: pathophysiology and etiology, or the what and why","volume":"27","author":"Schocket AL","year":"2006","journal-title":"Allergy Asthma Proc"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.04.040186.002223"},{"key":"e_1_2_9_6_1","first-page":"14","article-title":"Binding characteristics of human IgE receptors and initial triggering events in human mast cells for histamine release","volume":"18","author":"Ishizaka T","year":"1983","journal-title":"Monogr Allergy"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.11.017"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2013.07.009"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.04.036"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1986.tb04065.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02707.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2010.12.014"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.02.049"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.11.047"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215372"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.05.013"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.306"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125002171"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.08.011"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.993971"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.07.006"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.04.038"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.06.010"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02409.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.822484"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000320233"},{"key":"e_1_2_9_27_1","first-page":"41","article-title":"Extraordinary response to omalizumab in a child with severe chronic urticaria","volume":"46","author":"Asero R","year":"2014","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12450"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01591.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60644-8"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.8705"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200203040-00005"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-5-200003070-00004"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02325.x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-009-1730-4"},{"key":"e_1_2_9_36_1","unstructured":"FDA Novartis and Genentech.Xolair regulatory history and labelling from drugs@FDA. [WWW document]. URLhttp:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails(last accessed: 11 August 2014)."},{"key":"e_1_2_9_37_1","unstructured":"Novartis Pharmaceuticals UK Ltd.Xolair (omalizumab) 150\u00a0mg powder and solvent for solution for injection. UK summary of product characteristics. [WWW document]. Updated December 2013. URLhttp:\/\/www.medicines.org.uk\/emc\/medicine\/17029(last accessed: 13 January 2014)."},{"issue":"99","key":"e_1_2_9_38_1","first-page":"580s","article-title":"Omalizumab reduced symptoms and improved health\u2010related quality of life (HRQoL) in patients with refractory chronic spontaneous\/idiopathic urticaria (CSU\/CIU) in three randomised, double\u2010blind, placebo\u2010controlled phase III trials: a post\u2010hoc analysis of percent change from baseline","volume":"69","author":"Casale T","year":"2014","journal-title":"Allergy"},{"key":"e_1_2_9_39_1","unstructured":"CasaleT MaurerM SainiSSet\u00a0al.Omalizumab improved symptoms in all three phase III trials conducted in patients with inadequately controlled chronic spontaneous\/idiopathic urticaria (CSU\/CIU): a post\u2010hoc analysis of percent change from baseline. Allergy 2015; 70 (Suppl.6). Latebreaking abstract to be presented at EAACI 2015."},{"key":"e_1_2_9_40_1","unstructured":"RosenK KhalilS BalpM\u2010M MaurerM.Omalizumab improves quality of life (QoL) in patients with symptomatic chronic spontaneous\/idiopathic urticaria (CSU\/CIU) as assessed by the Dermatology Life Quality Index (DLQI). Presented at the Annual Meeting of the American Academy of Allergy Asthma and Immunology (AAAAI) Houston TX USA 20\u201324 February 2015 (Poster P409)."},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02178.x"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00962.x"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1994.tb04956.x"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(05)80245-3"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12547"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2013.09.010"},{"key":"e_1_2_9_47_1","unstructured":"European Academy of Allergy and Clinical Immunology (EAACI).Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology [draft guidance]. [WWW document]. 12 June 2013. URLhttp:\/\/www.eaaci.org\/attachments\/Anaphylaxis%20guidelines%20Draft%204.5%202013%2006%20.pdf(last accessed: 13 February 2014)."},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12661"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.1962.73"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb02593.x"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-012-0269-0"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.10-CR-0291"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0306"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2004.01.005"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1989.tb08195.x"},{"key":"e_1_2_9_56_1","first-page":"41","article-title":"Antihistamines in the treatment of chronic urticaria","volume":"17","author":"J\u00e1uregui I","year":"2007","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_9_57_1","unstructured":"Clinicaltrials.gov.Urticaria facticia treatment with omalizumab (UFO). (NCT02169115). [WWW document]. URLhttps:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02169115(last accessed: 2 March 2015)."},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.4.e313"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.12.008"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1159\/000336572"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2010.04.002"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10822.x"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2009.11.013"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12171"},{"key":"e_1_2_9_65_1","first-page":"255","article-title":"Cold\u2010induced urticaria","volume":"34","author":"Delorme N","year":"2002","journal-title":"Allerg Immunol (Paris)"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05414.x"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.10-OA-0269"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02767.x"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.7205\/MILMED.173.2.217"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04017.x"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12765"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12200"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1987.tb05877.x"},{"key":"e_1_2_9_74_1","first-page":"664","article-title":"Severe refractory cholinergic urticaria treated with danazol","volume":"5","author":"La Shell MS","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2013.1933"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10104.x"},{"key":"e_1_2_9_77_1","first-page":"296","article-title":"[Solar urticaria: pre\u2010PUVA UVA desensitization]","volume":"127","author":"Pont M","year":"2000","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.104517"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10944.x"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-7310(05)73028-3"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.08.020"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.6.765"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2011.00624.x"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2009.30.3273"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1963.01590200023004"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.1997.tb00109.x"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01879.x"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2009.01268.x"},{"key":"e_1_2_9_89_1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1610-0387.2011.07749.x","article-title":"Delayed pressure urticaria \u2013 dapsone heading for first\u2010line therapy?","volume":"9","author":"Grundmann SA","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2004.01.006"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2004.02019.x"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02678.x"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2007.00276.x"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2011.04281.x"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.12.658"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05486.x"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09538.x"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2010.01120.x"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e328305e262"},{"key":"e_1_2_9_100_1","first-page":"5","article-title":"Urticaria and urticaria related skin condition\/disease in children","volume":"40","author":"Novembre E","year":"2008","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-9572(08)60014-5"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-5-10"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0736-8046.2004.21202.x"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.069"},{"key":"e_1_2_9_105_1","doi-asserted-by":"publisher","DOI":"10.1159\/000322349"},{"issue":"2","key":"e_1_2_9_106_1","first-page":"28","article-title":"Use of antihistamines in pediatrics","volume":"17","author":"Cuvillo A","year":"2007","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild\u20102013\u2010304446"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.87.2.93"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-10-24"},{"key":"e_1_2_9_110_1","unstructured":"Merck & Co.SINGULAIR\u00ae(montelukast): prescribing information. [WWW document]. Updated June 2013. Available at:http:\/\/www.merck.com\/product\/usa\/pi_circulars\/s\/singulair\/singulair_pi.pdf(last accessed: 13 January 2014)."},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2009.00869.x"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.04.011"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2013.12.005"},{"key":"e_1_2_9_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.10.015"},{"key":"e_1_2_9_115_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936050-00003"},{"key":"e_1_2_9_116_1","first-page":"389","article-title":"Potential cardiac toxicity of H1\u2010antihistamines","volume":"17","author":"Yap YG","year":"2002","journal-title":"Clin Allergy Immunol"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.1177\/030006058801600106"},{"key":"e_1_2_9_118_1","doi-asserted-by":"publisher","DOI":"10.2174\/187231209789352067"},{"key":"e_1_2_9_119_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0047-3"},{"key":"e_1_2_9_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-013-0061-y"},{"key":"e_1_2_9_121_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.43203"},{"key":"e_1_2_9_122_1","unstructured":"Food and Drug Administration (FDA).FDA. 21 CFR part 201. 2008. [WWW document]. URLhttp:\/\/www.gpo.gov\/fdsys\/pkg\/FR-2008-05-29\/pdf\/E8-11806.pdf(last accessed: 20 January 2015)."},{"key":"e_1_2_9_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90208-2"},{"key":"e_1_2_9_124_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1988.tb03138.x"},{"key":"e_1_2_9_125_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1499"},{"key":"e_1_2_9_126_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.970164"},{"key":"e_1_2_9_127_1","doi-asserted-by":"publisher","DOI":"10.1080\/jmf.11.3.146.152"},{"key":"e_1_2_9_128_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.3.21"},{"key":"e_1_2_9_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2008.05.053"},{"key":"e_1_2_9_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2015.01.006"},{"key":"e_1_2_9_131_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005237-200209000-00004"},{"key":"e_1_2_9_132_1","first-page":"881","article-title":"Safety of using montelukast during pregnancy","volume":"56","author":"Koren G","year":"2010","journal-title":"Can Fam Physician"},{"key":"e_1_2_9_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12628"},{"key":"e_1_2_9_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.025"},{"key":"e_1_2_9_135_1","doi-asserted-by":"publisher","DOI":"10.5114\/pdia.2014.40975"},{"key":"e_1_2_9_136_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12260"},{"key":"e_1_2_9_137_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1975.tb06732.x"},{"key":"e_1_2_9_138_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5574.262"},{"key":"e_1_2_9_139_1","first-page":"210","article-title":"Subtypes of chronic urticaria in patients attending allergy clinics in Venezuela","volume":"46","author":"S\u00e1nchez\u2010Borges M","year":"2014","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"e_1_2_9_140_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12658"},{"key":"e_1_2_9_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.12.323"},{"key":"e_1_2_9_142_1","doi-asserted-by":"publisher","DOI":"10.1159\/000356702"},{"key":"e_1_2_9_143_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.14.1637"},{"key":"e_1_2_9_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2006.08.001"},{"key":"e_1_2_9_145_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90161-7"},{"key":"e_1_2_9_146_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0574"},{"key":"e_1_2_9_147_1","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2010.2.3.195"},{"key":"e_1_2_9_148_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1760"},{"key":"e_1_2_9_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60594-7"},{"key":"e_1_2_9_150_1","first-page":"333","article-title":"Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis","volume":"21","author":"Caballero T","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_9_151_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.d01-1160.x"},{"key":"e_1_2_9_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2007.09.038"},{"key":"e_1_2_9_153_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.2005.00819.x"},{"key":"e_1_2_9_154_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr\u20102013\u2010200652"},{"key":"e_1_2_9_155_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2010.03.032"},{"key":"e_1_2_9_156_1","unstructured":"Clinicaltrials.gov.Blinded safety and efficacy placebo controlled study of icatibant for angiotensin converting enzyme inhibitor induced angioedema. (NCT01919801). [WWW document]. URLhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01919801(last accessed: 2 March 2015)."},{"key":"e_1_2_9_157_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312524"},{"key":"e_1_2_9_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2014.12.007"},{"key":"e_1_2_9_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60860-5"},{"key":"e_1_2_9_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.04.003"},{"key":"e_1_2_9_161_1","doi-asserted-by":"publisher","DOI":"10.1159\/000346284"},{"key":"e_1_2_9_162_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03748.x"},{"key":"e_1_2_9_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.11.007"},{"key":"e_1_2_9_164_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02188.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13198","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13198","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T08:10:07Z","timestamp":1694592607000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":163,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/jdv.13198"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13198","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}